ESCMID*  ||| S:0 E:8 ||| NNP
guideline  ||| S:8 E:18 ||| NN
for  ||| S:18 E:22 ||| IN
the  ||| S:22 E:26 ||| DT
diagnosis  ||| S:26 E:36 ||| NN
and  ||| S:36 E:40 ||| CC
management  ||| S:40 E:51 ||| NN
of  ||| S:51 E:54 ||| IN
Candida  ||| S:54 E:62 ||| NNP
diseases  ||| S:62 E:71 ||| VBD
2012 ||| S:71 E:75 ||| CD
:  ||| S:75 E:77 ||| :
prevention  ||| S:77 E:88 ||| NN
and  ||| S:88 E:92 ||| CC
management  ||| S:92 E:103 ||| NN
of  ||| S:103 E:106 ||| IN
invasive  ||| S:106 E:115 ||| JJ
infections  ||| S:115 E:126 ||| NNS
in  ||| S:126 E:129 ||| IN
neonates  ||| S:129 E:138 ||| NN
and  ||| S:138 E:142 ||| CC
children  ||| S:142 E:151 ||| NNS
caused  ||| S:151 E:158 ||| VBN
by  ||| S:158 E:161 ||| IN
Candida  ||| S:161 E:169 ||| NNP
spp  ||| S:169 E:173 ||| FW
Invasive  ||| S:173 E:182 ||| FW
candidiasis  ||| S:182 E:194 ||| FW
( ||| S:194 E:195 ||| -LRB-
IC ||| S:195 E:197 ||| NNP
)  ||| S:197 E:199 ||| -RRB-
is  ||| S:199 E:202 ||| VBZ
a  ||| S:202 E:204 ||| DT
relatively  ||| S:204 E:215 ||| RB
common  ||| S:215 E:222 ||| JJ
syndrome  ||| S:222 E:231 ||| NN
in  ||| S:231 E:234 ||| IN
neonates  ||| S:234 E:243 ||| NN
and  ||| S:243 E:247 ||| CC
children  ||| S:247 E:256 ||| NNS
and  ||| S:256 E:260 ||| CC
is  ||| S:260 E:263 ||| VBZ
associated  ||| S:263 E:274 ||| VBN
with  ||| S:274 E:279 ||| IN
significant  ||| S:279 E:291 ||| JJ
morbidity  ||| S:291 E:301 ||| NN
and  ||| S:301 E:305 ||| CC
mortality ||| S:305 E:314 ||| NN
.  ||| S:314 E:316 ||| .
These  ||| S:316 E:322 ||| DT
guidelines  ||| S:322 E:333 ||| NNS
provide  ||| S:333 E:341 ||| VBP
recommendations  ||| S:341 E:357 ||| NNS
for  ||| S:357 E:361 ||| IN
the  ||| S:361 E:365 ||| DT
prevention  ||| S:365 E:376 ||| NN
and  ||| S:376 E:380 ||| CC
treatment  ||| S:380 E:390 ||| NN
of  ||| S:390 E:393 ||| IN
IC  ||| S:393 E:396 ||| NNP
in  ||| S:396 E:399 ||| IN
neonates  ||| S:399 E:408 ||| NN
and  ||| S:408 E:412 ||| CC
children ||| S:412 E:420 ||| NNS
.  ||| S:420 E:422 ||| .
Appropriate  ||| S:422 E:434 ||| JJ
agents  ||| S:434 E:441 ||| NNS
for  ||| S:441 E:445 ||| IN
the  ||| S:445 E:449 ||| DT
prevention  ||| S:449 E:460 ||| NN
of  ||| S:460 E:463 ||| IN
IC  ||| S:463 E:466 ||| NNP
in  ||| S:466 E:469 ||| IN
neonates  ||| S:469 E:478 ||| NN
at  ||| S:478 E:481 ||| IN
high  ||| S:481 E:486 ||| JJ
risk  ||| S:486 E:491 ||| NN
include  ||| S:491 E:499 ||| VBP
fluconazole  ||| S:499 E:511 ||| NNS
( ||| S:511 E:512 ||| -LRB-
A-I ||| S:512 E:515 ||| NNP
) ||| S:515 E:516 ||| -RRB-
,  ||| S:516 E:518 ||| ,
nystatin  ||| S:518 E:527 ||| NNS
( ||| S:527 E:528 ||| -LRB-
B-II ||| S:528 E:532 ||| NNP
)  ||| S:532 E:534 ||| -RRB-
or  ||| S:534 E:537 ||| CC
lactoferrin  ||| S:537 E:549 ||| JJ
Â±  ||| S:549 E:551 ||| NNP
Lactobacillus  ||| S:551 E:565 ||| NNP
( ||| S:565 E:566 ||| -LRB-
B-II ||| S:566 E:570 ||| NNP
) ||| S:570 E:571 ||| -RRB-
.  ||| S:571 E:573 ||| .
The  ||| S:573 E:577 ||| DT
treatment  ||| S:577 E:587 ||| NN
of  ||| S:587 E:590 ||| IN
IC  ||| S:590 E:593 ||| NNP
in  ||| S:593 E:596 ||| IN
neonates  ||| S:596 E:605 ||| NN
is  ||| S:605 E:608 ||| VBZ
complicated  ||| S:608 E:620 ||| VBN
by  ||| S:620 E:623 ||| IN
the  ||| S:623 E:627 ||| DT
high  ||| S:627 E:632 ||| JJ
likelihood  ||| S:632 E:643 ||| NN
of  ||| S:643 E:646 ||| IN
disseminated  ||| S:646 E:659 ||| JJ
disease ||| S:659 E:666 ||| NN
,  ||| S:666 E:668 ||| ,
including  ||| S:668 E:678 ||| VBG
the  ||| S:678 E:682 ||| DT
possibility  ||| S:682 E:694 ||| NN
of  ||| S:694 E:697 ||| IN
infection  ||| S:697 E:707 ||| NN
within  ||| S:707 E:714 ||| IN
the  ||| S:714 E:718 ||| DT
central  ||| S:718 E:726 ||| JJ
nervous  ||| S:726 E:734 ||| JJ
system ||| S:734 E:740 ||| NN
.  ||| S:740 E:742 ||| .
Amphotericin  ||| S:742 E:755 ||| NNP
B  ||| S:755 E:757 ||| NNP
deoxycholate  ||| S:757 E:770 ||| NNS
( ||| S:770 E:771 ||| -LRB-
B-II ||| S:771 E:775 ||| NNP
) ||| S:775 E:776 ||| -RRB-
,  ||| S:776 E:778 ||| ,
liposomal  ||| S:778 E:788 ||| FW
amphotericin  ||| S:788 E:801 ||| FW
B  ||| S:801 E:803 ||| NNP
( ||| S:803 E:804 ||| -LRB-
B-II ||| S:804 E:808 ||| NNP
) ||| S:808 E:809 ||| -RRB-
,  ||| S:809 E:811 ||| ,
amphotericin  ||| S:811 E:824 ||| JJ
B  ||| S:824 E:826 ||| NN
lipid  ||| S:826 E:832 ||| NN
complex  ||| S:832 E:840 ||| NN
( ||| S:840 E:841 ||| -LRB-
ABLC ||| S:841 E:845 ||| NNP
)  ||| S:845 E:847 ||| -RRB-
( ||| S:847 E:848 ||| -LRB-
C-II ||| S:848 E:852 ||| NNP
) ||| S:852 E:853 ||| -RRB-
,  ||| S:853 E:855 ||| ,
fluconazole  ||| S:855 E:867 ||| NNS
( ||| S:867 E:868 ||| -LRB-
B-II ||| S:868 E:872 ||| NNP
) ||| S:872 E:873 ||| -RRB-
,  ||| S:873 E:875 ||| ,
micafungin  ||| S:875 E:886 ||| NNS
( ||| S:886 E:887 ||| -LRB-
B-II ||| S:887 E:891 ||| NNP
)  ||| S:891 E:893 ||| -RRB-
and  ||| S:893 E:897 ||| CC
caspofungin  ||| S:897 E:909 ||| NNS
( ||| S:909 E:910 ||| -LRB-
C-II ||| S:910 E:914 ||| NNP
)  ||| S:914 E:916 ||| -RRB-
can  ||| S:916 E:920 ||| MD
all  ||| S:920 E:924 ||| RB
be  ||| S:924 E:927 ||| VB
potentially  ||| S:927 E:939 ||| RB
used ||| S:939 E:943 ||| VBN
.  ||| S:943 E:945 ||| .
Recommendations  ||| S:945 E:961 ||| NNS
for  ||| S:961 E:965 ||| IN
the  ||| S:965 E:969 ||| DT
prevention  ||| S:969 E:980 ||| NN
of  ||| S:980 E:983 ||| IN
IC  ||| S:983 E:986 ||| NNP
in  ||| S:986 E:989 ||| IN
children  ||| S:989 E:998 ||| NNS
are  ||| S:998 E:1002 ||| VBP
largely  ||| S:1002 E:1010 ||| RB
extrapolated  ||| S:1010 E:1023 ||| VBN
from  ||| S:1023 E:1028 ||| IN
studies  ||| S:1028 E:1036 ||| NNS
performed  ||| S:1036 E:1046 ||| VBN
in  ||| S:1046 E:1049 ||| IN
adults  ||| S:1049 E:1056 ||| NNS
with  ||| S:1056 E:1061 ||| IN
concomitant  ||| S:1061 E:1073 ||| JJ
pharmacokinetic  ||| S:1073 E:1089 ||| JJ
data  ||| S:1089 E:1094 ||| NNS
and  ||| S:1094 E:1098 ||| CC
models  ||| S:1098 E:1105 ||| NNS
in  ||| S:1105 E:1108 ||| IN
children ||| S:1108 E:1116 ||| NNS
.  ||| S:1116 E:1118 ||| .
For  ||| S:1118 E:1122 ||| IN
allogeneic  ||| S:1122 E:1133 ||| JJ
HSCT  ||| S:1133 E:1138 ||| NN
recipients ||| S:1138 E:1148 ||| NNS
,  ||| S:1148 E:1150 ||| ,
fluconazole  ||| S:1150 E:1162 ||| NNS
( ||| S:1162 E:1163 ||| -LRB-
A-I ||| S:1163 E:1166 ||| NNP
) ||| S:1166 E:1167 ||| -RRB-
,  ||| S:1167 E:1169 ||| ,
voriconazole  ||| S:1169 E:1182 ||| NNS
( ||| S:1182 E:1183 ||| -LRB-
A-I ||| S:1183 E:1186 ||| NNP
) ||| S:1186 E:1187 ||| -RRB-
,  ||| S:1187 E:1189 ||| ,
micafungin  ||| S:1189 E:1200 ||| NNS
( ||| S:1200 E:1201 ||| -LRB-
A-I ||| S:1201 E:1204 ||| NNP
) ||| S:1204 E:1205 ||| -RRB-
,  ||| S:1205 E:1207 ||| ,
itraconazole  ||| S:1207 E:1220 ||| NNS
( ||| S:1220 E:1221 ||| -LRB-
B-II ||| S:1221 E:1225 ||| NNP
)  ||| S:1225 E:1227 ||| -RRB-
and  ||| S:1227 E:1231 ||| CC
posaconazole  ||| S:1231 E:1244 ||| NNS
( ||| S:1244 E:1245 ||| -LRB-
B-II ||| S:1245 E:1249 ||| NNP
)  ||| S:1249 E:1251 ||| -RRB-
can  ||| S:1251 E:1255 ||| MD
all  ||| S:1255 E:1259 ||| RB
be  ||| S:1259 E:1262 ||| VB
used ||| S:1262 E:1266 ||| VBN
.  ||| S:1266 E:1268 ||| .
Similar  ||| S:1268 E:1276 ||| JJ
recommendations  ||| S:1276 E:1292 ||| NNS
are  ||| S:1292 E:1296 ||| VBP
made  ||| S:1296 E:1301 ||| VBN
for  ||| S:1301 E:1305 ||| IN
the  ||| S:1305 E:1309 ||| DT
prevention  ||| S:1309 E:1320 ||| NN
of  ||| S:1320 E:1323 ||| IN
IC  ||| S:1323 E:1326 ||| NNP
in  ||| S:1326 E:1329 ||| IN
children  ||| S:1329 E:1338 ||| NNS
in  ||| S:1338 E:1341 ||| IN
other  ||| S:1341 E:1347 ||| JJ
risk  ||| S:1347 E:1352 ||| NN
groups ||| S:1352 E:1358 ||| NNS
.  ||| S:1358 E:1360 ||| .
With  ||| S:1360 E:1365 ||| IN
several  ||| S:1365 E:1373 ||| JJ
exceptions ||| S:1373 E:1383 ||| NNS
,  ||| S:1383 E:1385 ||| ,
recommendations  ||| S:1385 E:1401 ||| NNS
for  ||| S:1401 E:1405 ||| IN
the  ||| S:1405 E:1409 ||| DT
treatment  ||| S:1409 E:1419 ||| NN
of  ||| S:1419 E:1422 ||| IN
IC  ||| S:1422 E:1425 ||| NNP
in  ||| S:1425 E:1428 ||| IN
children  ||| S:1428 E:1437 ||| NNS
are  ||| S:1437 E:1441 ||| VBP
extrapolated  ||| S:1441 E:1454 ||| VBN
from  ||| S:1454 E:1459 ||| IN
adult  ||| S:1459 E:1465 ||| NN
studies ||| S:1465 E:1472 ||| NNS
,  ||| S:1472 E:1474 ||| ,
with  ||| S:1474 E:1479 ||| IN
concomitant  ||| S:1479 E:1491 ||| JJ
pharmacokinetic  ||| S:1491 E:1507 ||| JJ
studies ||| S:1507 E:1514 ||| NNS
.  ||| S:1514 E:1516 ||| .
Amphotericin  ||| S:1516 E:1529 ||| NNP
B  ||| S:1529 E:1531 ||| NNP
deoxycholate  ||| S:1531 E:1544 ||| NNS
( ||| S:1544 E:1545 ||| -LRB-
C-I ||| S:1545 E:1548 ||| NNP
) ||| S:1548 E:1549 ||| -RRB-
,  ||| S:1549 E:1551 ||| ,
liposomal  ||| S:1551 E:1561 ||| FW
amphotericin  ||| S:1561 E:1574 ||| FW
B  ||| S:1574 E:1576 ||| NNP
( ||| S:1576 E:1577 ||| -LRB-
A-I ||| S:1577 E:1580 ||| NNP
) ||| S:1580 E:1581 ||| -RRB-
,  ||| S:1581 E:1583 ||| ,
ABLC  ||| S:1583 E:1588 ||| NNP
( ||| S:1588 E:1589 ||| -LRB-
B-II ||| S:1589 E:1593 ||| NNP
) ||| S:1593 E:1594 ||| -RRB-
,  ||| S:1594 E:1596 ||| ,
micafungin  ||| S:1596 E:1607 ||| NNS
( ||| S:1607 E:1608 ||| -LRB-
A-I ||| S:1608 E:1611 ||| NNP
) ||| S:1611 E:1612 ||| -RRB-
,  ||| S:1612 E:1614 ||| ,
caspofungin  ||| S:1614 E:1626 ||| NNS
( ||| S:1626 E:1627 ||| -LRB-
A-I ||| S:1627 E:1630 ||| NNP
) ||| S:1630 E:1631 ||| -RRB-
,  ||| S:1631 E:1633 ||| ,
anidulafungin  ||| S:1633 E:1647 ||| NNS
( ||| S:1647 E:1648 ||| -LRB-
B-II ||| S:1648 E:1652 ||| NNP
) ||| S:1652 E:1653 ||| -RRB-
,  ||| S:1653 E:1655 ||| ,
fluconazole  ||| S:1655 E:1667 ||| NNS
( ||| S:1667 E:1668 ||| -LRB-
B-I ||| S:1668 E:1671 ||| NNP
)  ||| S:1671 E:1673 ||| -RRB-
and  ||| S:1673 E:1677 ||| CC
voriconazole  ||| S:1677 E:1690 ||| NNS
( ||| S:1690 E:1691 ||| -LRB-
B-I ||| S:1691 E:1694 ||| NNP
)  ||| S:1694 E:1696 ||| -RRB-
can  ||| S:1696 E:1700 ||| MD
all  ||| S:1700 E:1704 ||| RB
be  ||| S:1704 E:1707 ||| VB
used ||| S:1707 E:1711 ||| VBN
.  ||| S:1711 E:1713 ||| .
